Ahead of Q4 earnings, IDXX eyes double-digit revenue and EPS growth, driven by CAG momentum, new diagnostics and steady Water ...

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's ...

Most readers would already know that IDEXX Laboratories' (NASDAQ:IDXX) stock increased by 7.5% over the past three months. Given that the market rewards strong financials in the long-term, we wonder ...

In its upcoming report, Idexx Laboratories (IDXX) is predicted by Wall Street analysts to post quarterly earnings of $2.93 per share, reflecting an increase of 11.8% compared to the same period last ...

In the latest quarter, 4 analysts provided ratings for IDEXX Laboratories (NASDAQ:IDXX), showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, ...

IDXX rides on strong CAG Diagnostics momentum and growing global software adoption, but currency pressure and solvency risks cloud the outlook.

IDEXX Laboratories has designated Michael Erickson to succeed Jonathan Mazelsky at the helm of the pet healthcare company later this year.

Fundsmith, an investment management firm based in London, has released its annual 2025 investor letter for its “Fundsmith Equity Fund.” A copy of the letter can be downloaded here. The fund focuses on ...

Upgraded IDEXX to 'Buy' with a $450 price target due to oncology business expansion and share repurchase program. IDEXX's oncology market entry with Cancer Dx panel in March 2025 could drive ...

It notched a beat-and-raise third quarter. It cited innovation and increased customer take-up as reasons for the solid growth it posted during the frame. Idexx published its third-quarter figures well ...

Baron Funds, an investment management company, released its “Baron Asset Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. US equities continued the previous ...